Review of drug recalls and quality of pharmaceutical products in Nepal.
COVID-19
health economics
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
04 07 2022
04 07 2022
Historique:
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
To evaluate the pattern of substandard and falsified pharmaceutical products recall in Nepal. We analysed drug recall notices issued by the Department of Drug Administration (DDA), Nepal, and systematically reviewed peer-reviewed research articles during January 2010 to December 2020. This study did not include human participants. However, data were collected from 72 drug recall notices issued by DDA and four research papers. A total of 346 pharmaceutical products were recalled during the reported period. The number of recalled pharmaceutical products has increased significantly over the past decade in Nepal. The most frequently recalled drugs were antimicrobials followed by gastrointestinal medicines, vitamins and supplements and pain and palliative medicines among others. Number of imported recalled drugs were slightly higher (42.2%) than domestic recalled drugs (40.7%). Sixty-two percentage of recalled drugs were substandard, 11% were falsified and remaining 27% were not registered at the DDA. Similarly, higher number of modern drugs (62%) were recalled than traditional ones (35%). Hand sanitisers used to minimise COVID-19 transmission contributed significantly to the list of recalled pharmaceutical products in 2020. Most of these sanitisers contained significant amounts of methanol (as high as 75% v/v) instead of appropriate amount of ethyl or isopropyl alcohol. The peer-reviewed research papers reported issues with labelling, unregistered drugs and drugs failed in several laboratory testing. Our analysis showed that number of recalls of substandard and falsified drugs are increasing in Nepal. Since the recall data in this paper did not include number of samples tested and location of samples collected, more studies to understand the prevalence of substandard and falsified drugs in Nepal is recommended.
Identifiants
pubmed: 35788073
pii: bmjopen-2021-053479
doi: 10.1136/bmjopen-2021-053479
pmc: PMC9255392
doi:
Substances chimiques
Counterfeit Drugs
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e053479Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Nepal Health Res Counc. 2015 Sep-Dec;13(31):233-40
pubmed: 27005718
Clin Pharmacol Ther. 2009 Jun;85(6):576-8
pubmed: 19451909
BMJ Open. 2013 Jul 24;3(7):
pubmed: 23883882
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32859648
Glob Health Res Policy. 2017 May 08;2:14
pubmed: 29202082
BMJ Glob Health. 2019 Sep 24;4(5):e001636
pubmed: 31637025
J Pharm Bioallied Sci. 2019 Jul-Sep;11(3):284-291
pubmed: 31555036
J Pharm Biomed Anal. 2021 Feb 5;194:113761
pubmed: 33234414
JAMA Netw Open. 2018 Aug 3;1(4):e181685
pubmed: 30646099
Eur J Pharm Sci. 2018 Jan 1;111:46-56
pubmed: 28943443
Int J Pharm Investig. 2015 Jan-Mar;5(1):13-9
pubmed: 25599028
Expert Opin Drug Saf. 2005 Jul;4(4):619-22
pubmed: 16011440
Am J Health Syst Pharm. 2016 Feb 15;73(4):235-40
pubmed: 26843501
Am J Infect Control. 2020 Jul;48(7):853-854
pubmed: 32360745
Int J Environ Res Public Health. 2018 Jul 09;15(7):
pubmed: 29987197
Lancet Glob Health. 2020 Jun;8(6):e754-e755
pubmed: 32278364
PLoS One. 2018 Feb 5;13(2):e0191778
pubmed: 29401474
Front Med (Lausanne). 2019 May 24;6:105
pubmed: 31179281
Clin Microbiol Rev. 2015 Apr;28(2):443-64
pubmed: 25788516
Mayo Clin Proc. 2004 Feb;79(2):188-94
pubmed: 14959914
Rev Panam Salud Publica. 2020 Oct 06;44:e125
pubmed: 33033498
J Pharm Policy Pract. 2018 Jun 07;11:13
pubmed: 29930813
JAMA Netw Open. 2018 Aug 3;1(4):e181662
pubmed: 30646106